Content about Asthma

July 13, 2012

Vitamin D deficiency is associated with poor lung function in asthmatic children treated with inhaled corticosteroids, according to a new study from researchers in Boston released Friday.

NEW YORK — Vitamin D deficiency is associated with poor lung function in asthmatic children treated with inhaled corticosteroids, according to a new study from researchers in Boston released Friday.

June 21, 2012

Homeopathic supplier King Bio currently is presenting a replacement alternative for patients still seeking relief for their minor asthma symptoms in its 
AsthmaCare product.


NEW YORK — Homeopathic supplier King Bio currently is presenting a replacement alternative for patients still seeking relief for their minor asthma symptoms in its 
AsthmaCare product.


June 21, 2012

Taken together, asthma and chronic obstructive pulmonary disease — which includes chronic bronchitis and emphysema — affect nearly 50 million Americans, or about 15% of the total U.S. population, according to statistics from such organizations as the Centers for Disease Control and Prevention.

Taken together, asthma and chronic obstructive pulmonary disease — which includes chronic bronchitis and emphysema — affect nearly 50 million Americans, or about 15% of the total U.S. population, according to statistics from such organizations as the Centers for Disease Control and Prevention. And combined, the two diseases cause more than 100,000 deaths per year. Fortunately, however, there is a wide range of treatments available for both, many of which work for both diseases.


June 19, 2012

AstraZeneca and Rigel Pharmaceuticals have entered an exclusive worldwide license agreement for the global development and commercialization of an investigational treatment for moderate to severe chronic asthma.

SOUTH SAN FRANCISCO, Calif. — AstraZeneca and Rigel Pharmaceuticals have entered an exclusive worldwide license agreement for the global development and commercialization of an investigational treatment for moderate to severe chronic asthma.

May 29, 2012

A unit of generic drug maker Mylan has settled with Sunovion Pharmaceuticals over a drug used to treat chronic obstructive pulmonary disease and asthma.

PITTSBURGH — A unit of generic drug maker Mylan has settled with Sunovion Pharmaceuticals over a drug used to treat chronic obstructive pulmonary disease and asthma.

Mylan announced Tuesday that it had reached a settlement in a patent litigation suit that Sunovion, which used to operate under the name Sepracor, had filed against Dey Pharma, now known as Mylan Specialty, concerning the drug Xopenex (levalbuterol hydrochloride).

May 23, 2012

Coughing, wheezing, difficulty breathing — many people have symptoms like these for a variety of reasons, ranging from common colds to smoke inhalation to running. While unpleasant, they’re usually not serious. But for many Americans, they’re the result of medical conditions that are chronic, dangerous and sometimes fatal.

Coughing, wheezing, difficulty breathing — many people have symptoms like these for a variety of reasons, ranging from common colds to smoke inhalation to running. While unpleasant, they’re usually not serious. But for many Americans, they’re the result of medical conditions that are chronic, dangerous and sometimes fatal.

May 23, 2012

Taken together, asthma and chronic obstructive pulmonary disease — which includes chronic bronchitis and emphysema — affect nearly 50 million Americans, or about 15% of the total U.S. population, according to statistics from such organizations as the Centers for Disease Control and Prevention. And combined, the two diseases cause more than 100,000 deaths per year. Fortunately, however, there is a wide range of treatments available for both, many of which work for both diseases.

Taken together, asthma and chronic obstructive pulmonary disease — which includes chronic bronchitis and emphysema — affect nearly 50 million Americans, or about 15% of the total U.S. population, according to statistics from such organizations as the Centers for Disease Control and Prevention. And combined, the two diseases cause more than 100,000 deaths per year. Fortunately, however, there is a wide range of treatments available for both, many of which work for both diseases.

May 16, 2012

In contrast to the most recent cough-cold season, which was characterized by a relative lack of upper respiratory illnesses, pharmacy shoppers with itchy eyes, runny noses and audible sneezes have been back in force this spring in search of allergy relief.

In contrast to the most recent cough-cold season, which was characterized by a relative lack of upper respiratory illnesses, pharmacy shoppers with itchy eyes, runny noses and audible sneezes have been back in force this spring in search of allergy relief. And those patients are gravitating toward the OTC aisle for their seasonal allergy needs now that the last of the second-generation antihistamines was made available without a prescription a year ago. 


May 16, 2012

Asthma is having a growing effect on the country's health, according to a new study.

ATLANTA — Asthma is having a growing effect on the country's health, according to a new study.

The Centers for Disease Control and Prevention released its "Asthma's Impact on the Nation" report Wednesday, based on data gathered using the "Asthma Call-back Survey" of people with the disease. An estimated 29.1 million American adults, or 12.7% of the total, have been diagnosed with asthma in their lifetimes, while 18.7 million, or 8.2%, still had asthma in 2010.

March 26, 2012

The Food and Drug Administration has approved a drug made by Teva for treating allergies, the company said Monday.

JERUSALEM — The Food and Drug Administration has approved a drug made by Teva for treating allergies, the company said Monday.

Teva announced the approval of Qnasl (beclomethasone dipropionate) for seasonal and year-round nasal allergies in patients ages 12 years and older. The company said the drug, a "dry" nasal aerosol, would become available next month.

March 20, 2012

Novartis has launched a new treatment for chronic obstructive pulmonary disease, the drug maker said Monday.

EAST HANOVER, N.J. — Novartis has launched a new treatment for chronic obstructive pulmonary disease, the drug maker said Monday.

Novartis Pharmaceuticals, the U.S. division of the Swiss drug manufacturer, announced the launch of Arcapta Neohaler (indacaterol inhalation powder) in the 75-mcg strength. The Food and Drug Administration approved the drug last July.

March 12, 2012

Melville, N.Y.-based Ascent Consumer Products late last month introduced a new delivery form to the nasal saline category — a dry salt inhaler branded InHalo — as a new solution to help break up mucous and promote nasal and bronchial drainage at the ECRM Cough & Cold and Allergy EPPS conference held here.

LAS VEGAS — Melville, N.Y.-based Ascent Consumer Products late last month introduced a new delivery form to the nasal saline category — a dry salt inhaler branded InHalo — as a new solution to help break up mucous and promote nasal and bronchial drainage at the ECRM Cough & Cold and Allergy EPPS conference held here.

March 9, 2012

The Food and Drug Administration has approved a version of a drug made by Teva that includes a dose counter, the drug maker said.

NORTH WALES, Pa. — The Food and Drug Administration has approved a version of a drug made by Teva that includes a dose counter, the drug maker said.

Teva announced the approval of the inhaled drug ProAir HFA (albuterol sulfate) with a dose counter for treating bronchospasm with reversible obstructive airway disease and preventing exercise-induced bronchospasm in patients ages 4 years and older. The dose counter is designed to help patients and caregivers keep track of the number of doses in the canister.

March 5, 2012

A drug under development by Teva Pharmaceutical Industries appears safe and effective in treating allergies, according to results of a late-stage clinical trial released Monday.

JERUSALEM — A drug under development by Teva Pharmaceutical Industries appears safe and effective in treating allergies, according to results of a late-stage clinical trial released Monday.

Teva said a 529-patient phase-3 trial of Qnasl (beclomethasone dipropionate) nasal aerosol showed the drug produced a "significant" improvement in patients with seasonal and perennial allergies. Patients received either 320 mcg of Qnasl or a placebo.

February 24, 2012

In preparation for spring, the American College of Allergy, Asthma and Immunology on Friday noted that avoiding certain fruits and vegetables, installing the proper air filters, closing the windows, filling any allergy prescriptions and consulting with an allergist can all prevent the delay of allergy symptom relief for more than 35 million Americans who suffer from seasonal allergies.

ARLINGTON HEIGHTS, Ill. — In preparation for spring, the American College of Allergy, Asthma and Immunology on Friday noted that avoiding certain fruits and vegetables, installing the proper air filters, closing the windows, filling any allergy prescriptions and consulting with an allergist can all prevent the delay of allergy symptom relief for more than 35 million Americans who suffer from seasonal allergies.

February 21, 2012

Sen. Charles Schumer on Tuesday announced that the Food and Drug Administration has agreed to conduct a full review of the safety and legality of the new caffeine inhaler AeroShot, distributed by Breathable Foods, which hit stores in New York and Boston this past month.

WASHINGTON — Sen. Charles Schumer on Tuesday announced that the Food and Drug Administration has agreed to conduct a full review of the safety and legality of the new caffeine inhaler AeroShot, distributed by Breathable Foods, which hit stores in New York and Boston this past month.

February 17, 2012

As of the beginning of February, the cough-cold season had yet to materialize and illness levels were only just beginning to climb. If that’s the case, then an expected illness peak in late February/early March would make the 2011-2012 cough, cold and flu season one of the later-peaking seasons in recent years.


As of the beginning of February, the cough-cold season had yet to materialize and illness levels were only just beginning to climb. If that’s the case, then an expected illness peak in late February/early March would make the 2011-2012 cough, cold and flu season one of the later-peaking seasons in recent years.


As of Jan. 21, overall incidence of upper respiratory illness this season was down 7.5% according to IMS Health, as compared with the 2010-2011 season.


February 17, 2012

Asthma has been becoming more relevant in the nonprescription aisles of late.

Asthma has been becoming more relevant in the nonprescription aisles of late. Even as Armstrong Pharmaceuticals phases out what was an almost $100 million-and-growing brand in Primatene Mist 
— the Food and Drug Administration has removed any inhalers containing 
chlorofluorocarbons from the market — homeopathic supplier King Bio is currently presenting an alternative in its AsthmaCare product.


February 17, 2012

One of the main plotlines of the big story called the drug industry over the past several years has been the patent cliff, the steady loss of patent protection on blockbuster primary care drugs and subsequent generic competition that has forced many drug companies to find new revenue streams.

One of the main plotlines of the big story called the drug industry over the past several years has been the patent cliff, the steady loss of patent protection on blockbuster primary care drugs and subsequent generic competition that has forced many drug companies to find new revenue streams. Much of this has taken place in the form of a gradual shift to specialty drugs for such conditions as cancers and autoimmune disorders, but recent developments have shown that primary care drugs may still have some steam left in them.


February 14, 2012

Generic drug maker Mylan plans to challenge a court decision that requires it to pay almost $20 million to a drug company whose product it tried to market as a generic.

PITTSBURGH — Generic drug maker Mylan plans to challenge a court decision that requires it to pay almost $20 million to a drug company whose product it tried to market as a generic.

Sunovion Pharmaceuticals sued Mylan and several subsidiaries in the U.S. District Court for the District of Delaware when the latter sought to market a generic version of Sunovion's Xopenex (levalbuterol hydrochloride) inhalation solution, a drug for asthma and chronic obstructive pulmonary disease. The jury's verdict includes an $18 million award.

January 25, 2012

Medical device maker PMD Healthcare has launched what it calls the first personal spirometer to monitor lung function, the company said.

ALLENTOWN, Pa. — Medical device maker PMD Healthcare has launched what it calls the first personal spirometer to monitor lung function, the company said.

PMD, based in Allentown, Pa., announced the launch of the Spiro PD, which recently received approval from the Food and Drug Administration. The device is designed to enable patients with such lung diseases as asthma, chronic obstructive pulmonary disease, cystic fibrosis and lung transplants "easily and accurately" monitor lung function anytime and anywhere.

November 9, 2011

Generic drug maker Mylan has bought rights to a drug delivery platform made by Pfizer that will allow it to make generic versions of two GlaxoSmithKline respiratory drugs, Mylan said Wednesday.

PITTSBURGH — Generic drug maker Mylan has bought rights to a drug delivery platform made by Pfizer that will allow it to make generic versions of two GlaxoSmithKline respiratory drugs, Mylan said Wednesday.

October 10, 2011

The Food and Drug Administration has approved a new product for chronic obstructive pulmonary disease made by Boehringer Ingelheim Pharmaceuticals, the drug maker said.

RIDGEFIELD, Conn. — The Food and Drug Administration has approved a new product for chronic obstructive pulmonary disease made by Boehringer Ingelheim Pharmaceuticals, the drug maker said.

October 4, 2011

Growing numbers of Americans with asthma and chronic obstructive pulmonary disease are driving innovation among drug makers, according to a new report by Frost & Sullivan.

MOUNTAIN VIEW, Calif. — Growing numbers of Americans with asthma and chronic obstructive pulmonary disease are driving innovation among drug makers, according to a new report by Frost & Sullivan.

September 27, 2011

There seems to be a significant presence of asthma among children with diabetes, and those with both chronic illnesses have a difficult time controlling their blood-sugar levels, according to new research.

NEW YORK — There seems to be a significant presence of asthma among children with diabetes, and those with both chronic illnesses have a difficult time controlling their blood-sugar levels, according to new research.